EMEA Genicular Artery Embolization Market - A Regional Analysis: Focus on Product Type, End User, and Region - Analysis and Forecast, 2026-2036

This report can be delivered within 1 working day.

Introduction to the EMEA Genicular Artery Embolization Market

The EMEA genicular artery embolization market, valued at $9.4 million in 2025, is projected to reach $54.8 million by 2036, registering a compound annual growth rate (CAGR) of 17.28% during 2026-2036.

The EMEA genicular artery embolization market is an emerging segment of interventional radiology focused on minimally invasive management of symptomatic knee osteoarthritis (OA). Genicular artery embolization involves the selective catheterization and embolization of abnormal genicular arterial branches supplying the knee joint to reduce pathological hypervascularity and neovascularity associated with osteoarthritis-related inflammation and pain. The procedure is being investigated as an additional treatment option for patients experiencing persistent symptoms despite conservative management, particularly those who are unsuitable for or wish to delay knee replacement surgery. The commercial market includes embolic agents and associated single-use procedural instruments, including microcatheters, guidewires, vascular access and closure devices, and other directly attributable consumables.

The market is evolving as clinical investigation increases, specialist interventional radiology capabilities expand, and embolic technologies specifically positioned for GAE are introduced. Permanent microspheres currently have the strongest established clinical and regulatory position in Europe, supported by GAE-specific CE-marked indications for Embozene and Embosphere Microspheres in September 2025. Meanwhile, temporary and resorbable embolic technologies are gaining attention through ongoing clinical development, offering differentiated approaches to vascular occlusion. Despite these developments, broader adoption remains constrained by inconsistent comparative clinical evidence, differences in patient selection and procedural techniques, and the absence of standardized GAE-specific reimbursement pathways across major EMEA healthcare systems.

Market Introduction

Genicular artery embolization has evolved from an investigational embolization technique toward a more structured interventional treatment approach for knee osteoarthritis. The procedure primarily targets abnormal synovial hypervascularity associated with chronic knee pain and is performed using angiographic guidance to identify and selectively embolize the relevant genicular arterial branches. Clinical practice generally involves patient assessment, referral from orthopedic or other musculoskeletal specialists, angiographic mapping, embolic-agent selection, and post-procedure monitoring. Treatment outcomes are commonly evaluated through pain and functional assessment measures, including the Visual Analog Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Knee injury and Osteoarthritis Outcome Score (KOOS).

The technology landscape includes permanent microspheres and temporary or transient embolic agents, with emerging resorbable technologies expanding the range of available treatment approaches. Embolic-agent selection is influenced by particle characteristics, duration of vascular occlusion, delivery control, physician familiarity, clinical evidence, and patient-specific treatment considerations. Europe represents the more established clinical market, with ongoing research and commercial adoption across countries including the U.K., Germany, and France. In comparison, adoption in the Middle East and Africa remains concentrated in selected specialist centers, although expanding interventional radiology services and increasing clinical interest are supporting the gradual introduction of GAE.

Industrial Impact

The EMEA genicular artery embolization market represents an emerging opportunity within the interventional radiology and minimally invasive musculoskeletal treatment landscape. Key market participants, including Merit Medical Systems, Inc., Siemens Healthineers (Varian), NEXTBIOMEDICAL CO., LTD., and Guerbet, are contributing to the development and commercialization of embolic technologies and associated procedural solutions. Increasing clinical interest in alternatives to conventional knee osteoarthritis management is encouraging manufacturers to focus on dedicated embolic-agent indications, controlled embolization characteristics, resorbable materials, and improved procedural compatibility. The growing availability of GAE-specific products is also supporting the transition from investigator-led clinical use toward more structured treatment practices. However, future commercial expansion will depend on stronger comparative clinical evidence, standardized patient-selection and referral pathways, physician training, and reimbursement development. As GAE adoption increases, demand for embolic agents and single-use interventional instruments is expected to expand, creating opportunities across established medical device manufacturers, specialist embolic technology developers, and healthcare institutions providing image-guided procedures.

Market Segmentation:

Segmentation 1: By Product Type

• Embolic Agents
• Instruments

Instruments to Lead the EMEA Genicular Artery Embolization Market (by Product Type)

On the basis of product type, instruments account for the largest share of the EMEA genicular artery embolization market. The segment's dominance is attributed to the multiple single-use devices required during GAE procedures, including microcatheters, guidewires, vascular access devices, and other catheter-based consumables. Selective catheterization of the genicular arteries requires precise vascular navigation and controlled delivery of embolic materials, generating recurring demand for specialized interventional instruments.

Segmentation 2: By End User

• Hospitals
• Outpatient Centers and Other Settings

Hospitals to Lead the EMEA Genicular Artery Embolization Market (by End User)

Hospitals are expected to maintain their dominant position in the EMEA genicular artery embolization market throughout the forecast period, primarily supported by established interventional radiology infrastructure, angiography suites, specialist operators, and multidisciplinary patient-management capabilities. GAE currently requires expertise in selective arterial catheterization, embolic delivery, and post-procedural assessment, making tertiary hospitals, academic medical centers, and specialist hospitals the principal treatment settings.

Segmentation 3: By Region

• Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest-of-Europe
• Middle East and Africa
  • U.A.E.
  • K.S.A.
  • South Africa
  • Rest-of-Middle East and Africa

Europe to Lead the EMEA Genicular Artery Embolization Market (by Region)

Europe is expected to maintain its leading position in the EMEA genicular artery embolization market throughout the forecast period, supported by established interventional imaging infrastructure, earlier clinical adoption, and increasing development of GAE-specific embolic technologies. The region has generated a growing body of prospective and randomized clinical evidence, with research activity across the U.K., Germany, France, and other European countries. The availability of CE-marked embolic agents specifically indicated for GAE has also strengthened the regional regulatory and commercial environment.

Recent Developments in the EMEA Genicular Artery Embolization Market

• In June 2026, NEXTBIOMEDICAL CO., LTD. entered into a distribution agreement with Terumo Europe for Nexsphere-F across selected markets in Europe, the Middle East, and Africa. The agreement expanded the commercial distribution network for the rapidly resorbable embolic technology and was intended to strengthen product accessibility across the region.
• In January 2026, Magle PharmaCept GmbH and Sirtex Medical expanded their existing exclusive partnership through a long-term agreement covering the broader embolization field. The collaboration strengthened the clinical-development and commercialization framework supporting degradable starch microsphere technologies and potential indication expansion.
• In November 2025, Magle PharmaCept GmbH completed a European medical device filing to extend the intended use of EmboCept S DSM 50 µm to genicular artery embolization for symptomatic knee osteoarthritis. The filing represented an advancement in the development of temporary and degradable embolic technologies for GAE.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Treatment Gap in Knee Osteoarthritis Management Driving Demand for Genicular Artery Embolization: Knee osteoarthritis represents a substantial source of chronic pain, functional limitation, and reduced mobility, with treatment traditionally progressing from conservative interventions to surgical management in advanced cases. However, patients experiencing persistent symptoms despite medication, physiotherapy, or intra-articular injections may not be suitable candidates for knee replacement surgery or may prefer to delay surgical intervention. This treatment gap is generating clinical interest in minimally invasive alternatives that can be incorporated into existing knee pain management pathways. Genicular artery embolization offers an image-guided approach targeting abnormal synovial hypervascularity associated with osteoarthritis-related inflammation. Increasing awareness of GAE among interventional radiologists and musculoskeletal specialists, alongside the development of referral pathways and clinical evidence, is expected to support market growth. Its adoption will nevertheless depend on demonstrating consistent clinical benefit and identifying appropriate patient populations.

Market Challenges

Inconsistent Clinical Evidence Constraining Broader Adoption of GAE: The expanding clinical evidence base for genicular artery embolization has demonstrated encouraging pain and functional outcomes in several observational and prospective studies; however, findings from randomized and sham-controlled trials remain inconsistent. Differences in patient characteristics, osteoarthritis severity, embolic-agent selection, procedural techniques, and follow-up duration contribute to variability in reported treatment outcomes. Some comparative studies have not demonstrated statistically significant improvements over sham treatment, creating uncertainty regarding the magnitude and durability of procedure-specific benefits. These limitations have influenced clinical guideline recommendations and reimbursement decisions, with routine adoption remaining restricted in several healthcare systems. In the U.K., NICE guidance continues to recommend GAE for knee osteoarthritis only in the context of research. The absence of standardized reimbursement pathways and established referral protocols further limits procedure availability. Consequently, broader commercialization will depend on larger comparative studies, longer-term outcomes, improved patient-selection criteria, and evidence supporting clinical and economic value.

Market Opportunities

Development of Temporary and Resorbable Embolic Agents Creating Opportunity for Product Differentiation in GAE: Advances in temporary and resorbable embolic materials are creating opportunities to address evolving procedural requirements and differentiate products within the EMEA genicular artery embolization market. Permanent microspheres currently have an established clinical and commercial position, while emerging technologies are being developed to provide controlled vascular occlusion followed by material degradation or resorption. Products and technologies such as Nexsphere-F, EmboCept S, LIPIOJOINT, and SakuraBead are expanding the development landscape for alternative embolization approaches. Potential advantages under investigation include controlled occlusion duration, predictable particle behavior, standardized preparation, and compatibility with selective vascular delivery. However, these attributes must be assessed against the need for durable pain relief, favorable safety outcomes, and acceptable retreatment requirements. Ongoing clinical research and indication-specific regulatory development are expected to create opportunities for manufacturers to establish differentiated embolic portfolios and strengthen their position in the emerging GAE treatment market.

How can this report add value to an organization?

Product/Innovation Strategy: The EMEA genicular artery embolization market has been segmented by product type, end user, and region. The report assesses permanent and temporary/transient embolic agents alongside microcatheters, guidewires, vascular access and closure devices, and other procedural consumables. It identifies opportunities for product differentiation through embolic particle characteristics, resorption profiles, controlled delivery, procedural compatibility, and clinical validation. Understanding technology evolution and physician product-selection preferences can help manufacturers align research and development activities with the emerging requirements of GAE procedures.

Growth/Marketing Strategy: The report evaluates the expansion of GAE across specialist interventional radiology centers, hospitals, and emerging outpatient settings, supported by country-level market estimates, addressable patient population analysis, procedure adoption trends, and embolic-agent utilization patterns. Regional coverage across Europe, the Middle East, and Africa enables companies to identify markets with established clinical activity and emerging growth potential. These insights support commercialization planning, geographic expansion, distribution partnerships, physician engagement, and strategies for developing clinical referral networks.

Competitive Strategy: The EMEA genicular artery embolization market includes established interventional medical device manufacturers and emerging developers of specialized embolic technologies. The report benchmarks major embolic platforms, procedural product portfolios, clinical development activities, competitive positioning, and strategic initiatives. It examines the evolving competitive environment across permanent microspheres, temporary and resorbable embolic technologies, and supporting interventional devices. These insights can help organizations evaluate technology differentiation, identify unmet clinical and procedural needs, assess potential partnerships, and develop market-entry and portfolio expansion strategies.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• Years from 2025 to 2036 have been considered for the EMEA genicular artery embolization market size estimation; 2025 has been considered the base year, and 2026 to 2036 the forecast period.
• The market includes embolic agents and associated single-use procedural instruments directly used in genicular artery embolization procedures performed for knee osteoarthritis.
• The embolic agents segment includes permanent and temporary/transient embolic agents, while the instruments segment includes microcatheters, guidewires, vascular access and closure devices, and other directly attributable procedural consumables.
• Market estimates have been developed across product type, end user, regional, and country-level segments using triangulated demand assumptions, addressable patient population estimates, procedural adoption, embolic-agent utilization, and product-specific revenue considerations.
• The analysis uses scientific publications, clinical trial registries, regulatory information, company disclosures, product portfolios, industry interviews, secondary research, and top-down and bottom-up market estimation approaches.
• Proxy indicators and extrapolation have been employed where direct market data are unavailable. Existing technologies are assumed to remain relevant during the forecast period, while future economic downturns are not explicitly incorporated into the market estimates.

Primary Research

The primary sources involve industry experts from the healthcare, medical device, and interventional radiology sectors, along with stakeholders operating across the genicular artery embolization value chain. Respondents include company executives, vice presidents, marketing directors, product managers, technology and innovation directors, physicians, and other industry professionals associated with embolic agents and procedural instruments. Primary research is used to obtain and validate qualitative and quantitative information concerning market adoption, embolic-agent preferences, procedural practices, competitive positioning, and regional commercial opportunities. The findings are triangulated with secondary research and market-engineering calculations.

The key data points taken from the primary sources include:

• validation and triangulation of all the numbers and graphs
• validation of report segmentations and key qualitative findings
• understanding the competitive landscape and business model
• current and proposed production values of a product by market players
• validation of the numbers of different segments of the market in focus
• percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
• Annual reports, SEC filings, and investors' presentations of the leading market players
• Company websites and a detailed study of their product portfolio
• Gold standard magazines, journals, white papers, press releases, and news articles
• Paid databases

The key data points taken from the secondary sources include:

• segmentations and percentage shares
• data for market value
• key industry trends of the top players in the market
• qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Boston Scientific Corporation
• Cook Medical
• Cordis
• CrannMed
• Guerbet
• Magle Chemoswed Holding AB (Magle PharmaCept GmbH)
• Merit Medical Systems, Inc.
• NEXTBIOMEDICAL CO., LTD.
• Siemens Healthineers (Varian)
• Sirtex Medical
• Terumo Corporation